A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

Phase 3Not Yet RecruitingNCT07816198

Addpharma Inc.354 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy

Condition or disease: Type 2 Diabetes Mellitus

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

354

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

AD-233ADRUG

PO, Once daily(QD), 24 weeks

AD-233BDRUG

PO, Once daily(QD), 24 weeks

AD-233CDRUG

PO, Once daily(QD), 24 weeks

AD-233D

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Other inclusions applied Exclusion Criteria: * Subjects with severe diabetic complications * Other exclusions applied

Outcomes

Primary Outcomes

Change in HbA1c(Hemoglobin a1c) from baseline at Week 24 after administration of IP(Investigator's Product)

Time frame: Baseline, Week 24

Central Contacts

Hanna Yang

CONTACT

82+01084267236 hnyang@addpharma.co.kr

Seong rae Kim, Principal Investigator

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.